The acquisition of Aptose Biosciences by Hanmi Pharmaceutical has been delayed due to ongoing Korean regulatory review processes. The parties remain committed to the transaction and are now targeting a closing date within June 2026. Aptose received an additional US$2.0 million advance from Hanmi under an existing US$11.9 million facility agreement. Total funding received by Aptose under the facility agreement now stands at US$9.9 million, with a final US$2.0 million expected shortly. The capital advances are intended to support the ongoing TUSCANY clinical trial for the treatment of newly diagnosed AML.